Record · inventcures.github.io
MagnetisMM-32: A phase 3 randomized study of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma (RRMM) and prior anti-CD38–directed therapy.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs · 30 September 2026 · 2 min read
A post on inventcures.github.io, published 30 September 2026, has not been cited by any blog yet (corpus.blog, measured 13 October 2026).
A record is what was published and who pointed at it. The text of the post is not shown here: read it at the source, or at its Wayback capture.
0blogs citing
| Period | Blogs | Links |
|---|---|---|
| All time | 0 | 0 |
| Last 90 days | 0 | 0 |
| Last 30 days | 0 | 0 |
| Last 7 days | 0 | 0 |
| Words blogs link it with | 0 |
|---|---|
| External links | 0 |
| Length | 412 |
Cited by
No blog we hold has cited this post yet.
Links from this post
This post links to no other pages.
Similar posts
Q&A October is ECTRIMS Month
multiple-sclerosis-research.org
1 Oct 2026
Is Cladribine inferior to B cell depletion
multiple-sclerosis-research.org
30 Sept 2026
Something wrong here? Report a problem